|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Halozyme Therapeutics, Inc.
| | | Phone: | (858) 794-8889 | Fax: | (858) 259-2539 | Year Established: | 1999 | Employees: | 109 | Ticker: | HTI | Exchange: | AMEX | Main Contact: | Helen Torley , M.B. Ch. B., M.R.C.P., President & CEO | | Other Contacts: | Homa Yeganegi, VP, Global Scientific and Medical Affairs Kristina Vlaovic, VP, Regulatory & Safety Laurie D. Stelzer, Senior VP & CFO Kenneth A. Schultz , M.D., VP, Innovation, Strategy and Business Development Michael J. LaBarre, Ph.D., VP & CSO Dimitrios Chondros, CMO William J. Fallon, VP, CMC Operations Harry J. Leonhardt , Esq., Senior VP, General Counsel Benjamin Hickey, CCO
| | Company Description | Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly and Bristol-Myers Squibb for its ENHANZE® drug delivery technology. | |
|
|
|
|
|